Enveric Biosciences Inc. - news published 259 - readings 4.381

BACK
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023

CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that research foundational to the development of the Company's EVM201 Series and EVM301 Series i ...

Continue reading
30.05.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023 - Form 8-K

Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023 CAMBRIDGE, Mass., May 30, 2023 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today anno ...

Continue reading
30.05.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Receives Notice of Allowance from USPTO for C4-Carboxylic Acid-substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug - Form 8-K

Enveric Biosciences Receives Notice of Allowance from USPTO for C4-Carboxylic Acid-substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug New composition of matter claims expand intellectual property for Enveric's EVM201 Series CAMBRIDGE, Mass., May 24, 2023 - Enveric Biosciences, Inc . (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotech ...

Continue reading
24.05.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders - Form 8-K

Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders Research highlights the potential of Enveric's EVM201 Series aimed at developing psilocin prodrugs with altered metabolic profiles that offer superior administration and treatment benefits, but reduce pharmacological expos ...

Continue reading
23.05.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences to Participate in 2023 BIO International Convention in Boston - Form 8-K

Enveric Biosciences to Participate in 2023 BIO International Convention in Boston CAMBRIDGE, Mass., May 19, 2023 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced ...

Continue reading
19.05.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin - Form 8-K

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin Intellectual property describes composition of matter claims governing Enveric's lead clinical candidate, EB-373, which is being developed for the treatment of anxiety disorder CAMBRIDGE, Mass., May 18, 2023 - Enveric Biosciences, Inc . (NASDAQ: ENVB) ("Enveric" or the "Com ...

Continue reading
18.05.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights May 15, 2023 Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatm ...

Continue reading
15.05.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Quarterly Report for Quarter Ending March 31, 2023 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File Numb ...

Continue reading
15.05.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Amendment to Notice of Sales of Unregistered Securities - Form D/A

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D Notice of Exempt Offering of Securities OMB APPROVAL OMB Number: 3235- ...

Continue reading
19.04.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results - Form 8-K

Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results Key Highlights ● Nominated EB-373 as lead development candidate for the treatment of anxiety disorders ● EB-373 is a next generation proprietary psilocin prodrug selected from Enveric's EVM201 Series and developed leveraging the Company's Psybrary™ drug discovery platform ● Est ...

Continue reading
03.04.2023
Enveric Biosciences Inc.

Enveric Biosciences Inc.

Annual Report for Fiscal Year Ending December 31, 2022 (Form 10-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31 , 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File Number ...

Continue reading
31.03.2023